RxDoctor Payments Data

Leana Oppenheim, DO

Neurology · St Petersburg, FLNPI 1326487174

Payments from drug & device makers

$45,065in general payments, 2019–2025

Across 496 payments — averaging $90.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$35K
  • Brainsway USA Inc$693
  • UCB, Inc.$653
  • Biogen$641
  • Pfizer$523
  • Novartis$520
  • plus $7K from 54 others

What the payments were for

  • Speaking & faculty fees$32,56872%
  • Travel & lodging$7832%
  • Food & beverage$11,60326%
  • Education$1110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)120$35,175
Brainsway USA Inc1$693
UCB, Inc.26$653
Biogen25$641
Pfizer29$523
Novartis28$520
AstraZeneca(2 entities)16$446
GE HealthCare15$435
Neurocrine Biosciences, Inc.14$386
Takeda Pharmaceuticals U.S.A., Inc.13$377
Teva Pharmaceuticals USA, Inc.19$369
Argenx US, Inc.10$352
Vanda Pharmaceuticals Inc.10$318
Tanabe Pharma America, Inc.10$308
Lundbeck LLC10$289
Amgen(2 entities)11$259
Sunovion Pharmaceuticals Inc.8$224
Acorda Therapeutics, Inc9$215
Lilly USA, LLC10$199
Catalyst Pharmaceuticals, Inc.6$180
Medtronic(2 entities)2$170
Eisai Inc.8$165
Biohaven Pharmaceuticals, Inc.3$163
CSL Behring6$148
Genentech USA, Inc.5$113
Johnson & Johnson(2 entities)5$108
Sumitomo Pharma America, Inc.6$106
SK Life Science, Inc.3$99
Jazz Pharmaceuticals Inc.4$96
Sanofi3$94
TG Therapeutics, Inc.3$89
Banner Life Sciences, LLC3$72
Axsome Therapeutics, Inc.3$71
Upsher-smith Laboratories LLC3$70
Supernus Pharmaceuticals, Inc.5$63
Neurelis, Inc.3$62
Bristol Myers Squibb3$51
Otsuka America Pharmaceutical, Inc.2$50
Acadia Pharmaceuticals Inc2$49
Biohaven Pharmaceutical Holding Company Ltd.2$49
Harmony Biosciences LLC2$49
Merz Pharmaceuticals, LLC2$47
Portola Pharmaceuticals, LLC3$47
Impel Pharmaceuticals LLC2$45
Microtransponder, Inc.2$45
Grifols USA, LLC2$42
C2n Diagnostics, LLC2$42
Aucta Pharmaceuticals, Inc.3$41
Sarepta Therapeutics, Inc.1$29
Nevro Corp.2$29
Alnylam Pharmaceuticals Inc.1$29
Zyla Life Sciences, Inc.2$28
Impel Pharmaceuticals Inc.1$23
Xeris Pharmaceuticals, Inc.1$20
Corium, LLC1$19
Cycle Pharmaceuticals Inc1$18
Idorsia Pharmaceuticals US Inc1$16
EMD Serono, Inc.1$15
Amneal Pharmaceuticals LLC1$14
Avanir Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,065 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$80,153
Medicare patients
218
Services billed
3,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant86$112,198
UbrelvyUbrogepant64$81,226
Nurtec OdtRimegepant Sulfate43$76,378
BotoxOnabotulinumtoxina19$24,347
Aimovig AutoinjectorErenumab-Aooe21$20,033
Emgality PenGalcanezumab-Gnlm21$15,882
Memantine Hcl218$6,935
Rivastigmine28$3,371
Carbidopa-LevodopaCarbidopa/Levodopa107$2,603
Donepezil Hcl233$2,107
Gabapentin149$1,985
Levetiracetam64$1,928
Baclofen83$1,691
Pregabalin59$1,576
RizatriptanRizatriptan Benzoate33$1,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Botox$35,175$217,772169 claims
PfizerNurtec Odt$523$76,37843 claims
Upsher-smith Laboratories LLCTopiramate$70$63449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →